Verzenio (Abemaciclib)
abemaciclib
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Adjuvant early breast cancer — node-positive, high risk | HR+/HER2−, node+, adults | Combination (+ tamoxifen or AI) | FDA Approved |
| Advanced/metastatic — initial endocrine therapy | HR+/HER2− adults | Combination (+ AI) | FDA Approved |
| Advanced/metastatic — after endocrine progression | HR+/HER2− adults | Combination (+ fulvestrant) | FDA Approved |
| Advanced/metastatic — after endocrine + chemotherapy | HR+/HER2− adults | Monotherapy | FDA Approved |
Abemaciclib is unique among CDK4/6 inhibitors in several respects: it is the only one with a monotherapy indication, it is dosed continuously without a scheduled 7-day break, it is dosed twice daily (reflecting a shorter half-life of ~18 hours), and it can be used with tamoxifen (unlike ribociclib). Abemaciclib also crosses the blood-brain barrier, with CSF concentrations comparable to unbound plasma levels. The monarchE trial established the adjuvant role (iDFS 85.5% vs 78.6% at 4 years; HR 0.653). MONARCH 2 showed OS benefit with fulvestrant (HR 0.757; P=0.01). MONARCH 3 showed OS benefit with AI (median OS 67.1 vs 54.5 months; HR 0.804; P=0.0301). Diarrhea is the hallmark toxicity (81–90% across trials), distinguishing abemaciclib from palbociclib and ribociclib where neutropenia predominates.
Abemaciclib is the only CDK4/6 inhibitor approved as monotherapy, dosed twice daily continuously (no 7-day off period), compatible with tamoxifen, and able to penetrate the blood-brain barrier. Its primary toxicity is diarrhea (not neutropenia), and it has the highest rate of ILD/pneumonitis among CDK4/6 inhibitors (3–3.3% vs 1–1.6% for others). These pharmacological differences reflect its greater CDK4 selectivity relative to CDK6.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Schedule | Duration | Notes |
|---|---|---|---|---|
| Adjuvant early BC (monarchE) | 150 mg PO twice daily | Continuous (no off period) | 2 years (or until recurrence/toxicity) | With tamoxifen or AI Pre/perimenopausal or male: add GnRH agonist with AI |
| Advanced/metastatic + AI (MONARCH 3) | 150 mg PO twice daily | Continuous | Until progression/toxicity | With or without food Pre/perimenopausal or male: add GnRH agonist |
| Advanced/metastatic + fulvestrant (MONARCH 2) | 150 mg PO twice daily | Continuous | Until progression/toxicity | Fulvestrant 500 mg Days 1, 15, 29, then monthly Pre/perimenopausal: add GnRH agonist |
| Monotherapy (MONARCH 1) | 200 mg PO twice daily | Continuous | Until progression/toxicity | After prior endocrine therapy + chemo in metastatic setting |
| With strong CYP3A inhibitor (not ketoconazole) | 100 mg PO twice daily | Continuous | Per indication | Resume prior dose after 3–5 half-lives of inhibitor. If already at 100 mg BID for toxicity, reduce to 50 mg BID |
| With ketoconazole | AVOID — predicted 16-fold AUC increase | |||
| Severe hepatic impairment (Child-Pugh C) | Reduce frequency to once daily | Once daily | Per indication | No adjustment for mild/moderate (Child-Pugh A–B) |
Dose Reductions for Toxicity
| Level | Combination Dose | Monotherapy Dose |
|---|---|---|
| Starting | 150 mg BID | 200 mg BID |
| 1st reduction | 100 mg BID | 150 mg BID |
| 2nd reduction | 50 mg BID | 100 mg BID |
| 3rd reduction | N/A — discontinue | 50 mg BID |
| Cannot tolerate 50 mg BID | Discontinue abemaciclib | |
Unlike palbociclib and ribociclib where neutropenia drives dose modifications, diarrhea is the primary toxicity with abemaciclib (81–90% across trials). Instruct patients to start loperamide at the FIRST sign of loose stools. Median onset is 6–8 days. Most diarrhea occurs in the first month. Grade 2 diarrhea lasting >24 hours despite supportive care warrants dose interruption. Grade 3–4 or diarrhea requiring hospitalization warrants both dose interruption and subsequent dose reduction. Proactive management dramatically reduces the need for discontinuation.
Pharmacology
Mechanism of Action
Abemaciclib is a selective, reversible inhibitor of CDK4 and CDK6 with approximately 14-fold greater potency for CDK4/cyclin D1 over CDK6/cyclin D3 in enzymatic assays, making it the most CDK4-selective of the three approved CDK4/6 inhibitors. This selectivity is hypothesized to underlie its continuous dosing schedule and its activity as monotherapy. By blocking Rb phosphorylation, abemaciclib arrests the cell cycle in G1. Its ability to cross the blood-brain barrier (CSF concentrations comparable to unbound plasma levels) is pharmacologically distinctive, as neither palbociclib nor ribociclib achieves meaningful CNS penetration at therapeutic doses. Abemaciclib has three pharmacologically active metabolites (M2, M18, M20), which together account for approximately 45% of total plasma drug-derived exposure.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability 45%; Tmax ~8 h (range 4.1–24 h); no clinically significant food effect; dose-proportional (50–200 mg); accumulation ratio 2.3–3.2 | Can take with or without food; slow absorption explains delayed Tmax vs other CDK4/6i |
| Distribution | Vd ~690 L; protein binding ~96.3% (albumin, AAG); CSF concentrations comparable to unbound plasma; blood-to-CSF penetration confirmed | Crosses BBB — unique among CDK4/6 inhibitors; potential activity in brain metastases (investigational) |
| Metabolism | CYP3A4 (primary); active metabolites M2 (N-desethyl), M18, M20 (hydroxy derivatives) account for ~45% of plasma drug activity; parent ~55% | Active metabolites make total drug activity less dependent on parent compound alone; ketoconazole predicted to increase AUC 16-fold (avoid); clarithromycin increases AUC 3.4-fold |
| Elimination | t½ 18.3 h (mean); feces 81%, urine 3%; CL 24 L/h; steady state by day 5 | Shorter t½ mandates BID dosing (vs once daily for palbociclib/ribociclib); continuous dosing without scheduled breaks |
Side Effects
Data from FDA prescribing information (Feb 2025). monarchE (N=2791, abemaciclib + endocrine therapy) provides adjuvant data. MONARCH 3 (N=327, + AI) and MONARCH 2 (N=441, + fulvestrant) provide advanced data. Diarrhea is the defining toxicity of abemaciclib (81–90%), in contrast to neutropenia for palbociclib/ribociclib.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea | 84% | Grade 3: 8%; median onset 6–8 days; loperamide at first sign of loose stools; 20% required dose interruption, 17% dose reduction, 5% discontinuation |
| Infections | 51% | Grade 3: 4.9%, Grade 4: 0.6%; most common: URTI, UTI, nasopharyngitis |
| Neutropenia | 46% | Grade 3: 19%, Grade 4: 1.2%; median onset Gr≥3: 29–33 days; dose interruption 16%, dose reduction 8%, discontinuation 0.9% |
| Fatigue / Asthenia | 41% | Grade 3: 2.9%; dose-limiting in some patients (2% discontinuation, 5% reduction) |
| Nausea | 30% | Grade 3: 0.5%; usually mild |
| Anemia | 23% | Grade 3: 1.1%; monitor with CBC |
| Leukopenia | 21% | Grade 3: 6%; correlates with neutropenia pattern; dose interruption 7% |
| Headache | 20% | Grade 3: 0.3% |
| Vomiting | 18% | Grade 3: 0.5% |
| Stomatitis | 14% | Grade 3: 0.1%; includes mouth ulceration, mucosal inflammation |
| Decreased appetite | 12% | Grade 3: 0.6% |
| Dizziness | 11% | Grade 3: 0.1% |
| Rash | 11% | Grade 3: 0.5% |
| Alopecia | 10% | Non-graded; less common than with palbociclib/ribociclib (33%) |
| Abdominal pain | 10% | Grade 3: 0.5% |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Venous thromboembolism | 2–5% | Includes DVT, PE, pelvic venous thrombosis; fatal cases reported; higher than palbociclib/ribociclib |
| ILD / Pneumonitis | 3–3.3% | Grade 3–4: 0.4–0.6%; fatal: 0.1–0.4%; highest rate among CDK4/6 inhibitors |
| Febrile neutropenia | <1% | Two deaths from neutropenic sepsis in MONARCH 2 |
| Adverse Effect | Estimated Frequency | Details | Required Action |
|---|---|---|---|
| Severe diarrhea with dehydration/infection | Grade 3: 8–20% across trials | Median onset 6–8 days; Gr2 median duration 6–11 days; Gr3 median duration 5–8 days | Loperamide at first loose stool; increase oral fluids. Gr3/4 or hospitalization: suspend, reduce dose on resumption. Fatal diarrhea reported (0.03% monarchE). |
| Grade ≥3 Neutropenia | 19–32% | Median onset Gr≥3: 29–33 days; median duration: 11–16 days | CBC every 2 weeks ×2 months, then monthly ×2 months. Febrile neutropenia <1%; two deaths (MONARCH 2). |
| ILD / Pneumonitis | 3–3.3% any grade; Gr3-4: 0.4–0.6%; fatal: 0.1–0.4% | Variable | Permanently discontinue for Grade 3–4. Dose reduce for persistent/recurrent Grade 2. Highest ILD rate among CDK4/6 inhibitors. |
| Hepatotoxicity | Gr≥3 ALT: 2–6%; Gr≥3 AST: 2–3% | Median onset Gr≥3 ALT: 57–87 days; resolution: 13–14 days | LFTs every 2 weeks ×2 months, then monthly ×2 months. Discontinue if ALT/AST >3× ULN + bilirubin >2× ULN. |
| Venous Thromboembolism | 2–5% | Variable; includes DVT, PE, pelvic venous thrombosis | Early BC: suspend any grade VTE. Advanced: suspend Grade 3–4 VTE. Fatal cases reported. Not studied in early BC patients with VTE history. |
Diarrhea occurs in 81–90% of patients and is the primary reason for dose modification and discontinuation. Unlike chemotherapy-induced diarrhea, abemaciclib-related diarrhea typically begins in the first week (median 6–8 days), peaks during the first month, and improves with ongoing therapy. Proactive management is critical: prescribe loperamide to have on hand BEFORE starting, instruct patients to take loperamide at the FIRST sign of loose stools (not to wait for watery diarrhea), ensure adequate hydration, and follow up within the first 2 weeks. The 19–26% dose interruption rate and 13–23% dose reduction rate reflect primarily diarrhea management. Dose reductions for diarrhea do not appear to compromise efficacy based on exposure-response analyses.
Drug Interactions
Abemaciclib is metabolized primarily by CYP3A4 to active metabolites. Unlike palbociclib and ribociclib, both strong AND moderate CYP3A inducers should be avoided. Ketoconazole is specifically contraindicated (predicted 16-fold AUC increase). Abemaciclib increases serum creatinine via OCT2/MATE inhibition without true renal injury.
Monitoring
- CBC with DifferentialBaseline, every 2 weeks ×2 months, monthly ×2 months, then as indicated
RoutineNeutropenia 37–46%; Gr≥3: 19–32%. Median onset Gr≥3: 29–33 days. CBC monitoring schedule differs from palbociclib (which is Day 1 + Day 15). - Liver Function TestsBaseline, every 2 weeks ×2 months, monthly ×2 months, then as indicated
RoutineGr≥3 ALT: 2–6%; Gr≥3 AST: 2–3%. Discontinue if ALT/AST >3× ULN + bilirubin >2× ULN. - Stool Frequency / Diarrhea AssessmentFirst 2 weeks, then every visit
RoutineDiarrhea in 81–90%. Early contact (within first 2 weeks) is essential. Ensure loperamide is prescribed and patient understands to start at first loose stool. - Pregnancy TestBefore initiation
RoutineAbemaciclib is teratogenic. Verify pregnancy status in females of reproductive potential. - VTE SymptomsEvery visit
Trigger-basedVTE in 2–5%. Includes DVT, PE, pelvic venous thrombosis. Fatal cases reported. Not studied in early BC patients with VTE history. - Respiratory SymptomsEvery visit
Trigger-basedILD in 3–3.3%. Permanently discontinue for Grade 3–4. Highest ILD rate among CDK4/6 inhibitors. - Serum CreatinineAs indicated
Trigger-basedMean increase 0.2–0.3 mg/dL (OCT2/MATE inhibition, not nephrotoxicity). Use cystatin C or BUN if true renal function assessment needed.
Contraindications & Cautions
Absolute Contraindications
- The FDA prescribing information lists no formal absolute contraindications.
- Concurrent ketoconazole — predicted 16-fold AUC increase; must avoid.
Relative Contraindications (Specialist Input Recommended)
- Active severe diarrheal illness — resolve before initiating abemaciclib; baseline diarrhea may worsen significantly.
- Prior Grade 3–4 ILD on another CDK4/6 inhibitor — abemaciclib has the highest ILD rate in this class.
- History of VTE — VTE in 2–5%; not studied in early BC patients with prior VTE.
- Severe hepatic impairment (Child-Pugh C) — reduce dosing frequency to once daily; half-life increases to ~55 hours.
Use with Caution
- Concurrent strong CYP3A inhibitors (non-ketoconazole) — reduce to 100 mg BID.
- Concurrent moderate CYP3A inhibitors — monitor and consider 50 mg decrements.
- Elderly patients — higher frequency of hematologic AEs, hypokalemia, hypocalcemia, and severe infections.
- East Asian patients — may experience higher frequency of adverse events.
Abemaciclib can cause fetal harm. Teratogenicity and decreased fetal weight observed at maternal exposures similar to human clinical exposure. Females of reproductive potential must use effective contraception during treatment and for at least 3 weeks after the last dose. Verify pregnancy status before initiation. Do not breastfeed during treatment or for 3 weeks after the last dose.
Patient Counselling
Purpose of Therapy
Abemaciclib is a targeted therapy that blocks CDK4 and CDK6, slowing cancer cell division. Unlike similar medications, it is taken twice daily without a scheduled week off. For early breast cancer, treatment lasts 2 years.
How to Take
Take abemaciclib at approximately the same times every day, about 12 hours apart, with or without food. Swallow tablets whole. If a dose is missed or vomiting occurs, take the next dose at its usual time. Have loperamide (Imodium) ready before starting treatment.
Sources
- VERZENIO (abemaciclib) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; revised February 2025. DailyMedPrimary source for all dosing, adverse reaction incidence rates, pharmacokinetics, warnings, and dose modification tables.
- FDA approval of Verzenio (abemaciclib) with endocrine therapy for HR+, HER2−, node-positive early breast cancer at high risk of recurrence. FDA News, March 3, 2023. FDA.govOfficial FDA announcement of adjuvant indication based on monarchE trial data.
- Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998. doi:10.1200/JCO.20.02514monarchE primary analysis: abemaciclib + ET improved iDFS (HR 0.747; P=0.0096) in high-risk early BC.
- Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32(12):1571-1581. doi:10.1016/j.annonc.2021.09.015monarchE updated analysis with Ki-67 data; confirmed benefit in Ki-67 ≥20% subgroup. 4-year data (iDFS 85.5% vs 78.6%; HR 0.653) from subsequent update supported 2023 FDA expanded approval.
- Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646. doi:10.1200/JCO.2017.75.6155MONARCH 3 primary PFS: abemaciclib + AI PFS 28.2 vs 14.8 months (HR 0.54; P<0.001).
- Goetz MP, Toi M, Huober J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35(8):718-727. doi:10.1016/j.annonc.2024.04.013MONARCH 3 final OS: median 67.1 vs 54.5 months (HR 0.804; P=0.0301); significant OS benefit.
- Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884. doi:10.1200/JCO.2017.73.7585MONARCH 2 primary PFS: abemaciclib + fulvestrant PFS 16.4 vs 9.3 months (HR 0.553; P<0.001).
- Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in HR+, ERBB2− breast cancer that progressed on endocrine therapy — MONARCH 2. JAMA Oncol. 2020;6(1):116-124. doi:10.1001/jamaoncol.2019.4782MONARCH 2 OS: significant OS benefit (HR 0.757; P=0.01); confirmed in endocrine-pretreated patients.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2025. NCCN.orgPositions CDK4/6 inhibitors (including abemaciclib) + endocrine therapy as preferred first-line for HR+/HER2− advanced breast cancer; includes adjuvant abemaciclib recommendations.
- Posada MM, Morse BL, Turner PK, et al. Predicting clinical effects of CYP3A4 modulators on abemaciclib and active metabolites exposure using PBPK modeling. J Clin Pharmacol. 2020;60(7):915-930. doi:10.1002/jcph.1584PBPK analysis: bioavailability 45%, Vdss 724 L, CL 24 L/h; clarithromycin 3.4-fold increase, ketoconazole predicted 16-fold, rifampin 95% decrease.